RATIONALE: Potential mechanisms of action of topiramate include alterations of glutamatergic and GABAergic systems. In particular, topiramate has been shown to increase occipital cortex GABA levels, as measured using proton magnetic resonance spectroscopy (MRS). OBJECTIVES: The purpose of this study was to measure the effect of acute oral topiramate on the GABA precursors glutamate and glutamine in the anterior cingulate cortex (ACC) and occipital lobe (OL) using high-field (4.0 T) proton MRS (1H MRS). METHODS: Proton MR spectra were acquired from healthy men at three times: at baseline and 2 and 6 h after ingesting 50 (N=5) or 100 mg (N=5) of topiramate. Blood samples were acquired prior to each scan for the purpose of obtaining serum topiramate levels. RESULTS: A 100-mg dose of topiramate significantly increased ACC glutamine levels within 2 h of ingestion and OL glutamine levels within 6 h of ingestion. There were no measured significant effects of topiramate on ACC or OL glutamate levels. CONCLUSIONS: A 100-mg dose of oral topiramate increased serum topiramate and ACC glutamine levels within 2 h. OL glutamine levels increased within 6 h. Increased brain glutamine levels may be a consequence of topiramate positively modulating GABAA receptors. This result is of interest given the possible role for topiramate in the treatment of epilepsy, migraine headache, bipolar disorder, eating disorders, and alcohol dependence.
RATIONALE: Potential mechanisms of action of topiramate include alterations of glutamatergic and GABAergic systems. In particular, topiramate has been shown to increase occipital cortex GABA levels, as measured using proton magnetic resonance spectroscopy (MRS). OBJECTIVES: The purpose of this study was to measure the effect of acute oral topiramate on the GABA precursors glutamate and glutamine in the anterior cingulate cortex (ACC) and occipital lobe (OL) using high-field (4.0 T) proton MRS (1HMRS). METHODS: Proton MR spectra were acquired from healthy men at three times: at baseline and 2 and 6 h after ingesting 50 (N=5) or 100 mg (N=5) of topiramate. Blood samples were acquired prior to each scan for the purpose of obtaining serum topiramate levels. RESULTS: A 100-mg dose of topiramate significantly increased ACC glutamine levels within 2 h of ingestion and OL glutamine levels within 6 h of ingestion. There were no measured significant effects of topiramate on ACC or OL glutamate levels. CONCLUSIONS: A 100-mg dose of oral topiramate increased serum topiramate and ACC glutamine levels within 2 h. OL glutamine levels increased within 6 h. Increased brain glutamine levels may be a consequence of topiramate positively modulating GABAA receptors. This result is of interest given the possible role for topiramate in the treatment of epilepsy, migraineheadache, bipolar disorder, eating disorders, and alcohol dependence.
Authors: Pamela L Follett; Wenbin Deng; Weimin Dai; Delia M Talos; Leon J Massillon; Paul A Rosenberg; Joseph J Volpe; Frances E Jensen Journal: J Neurosci Date: 2004-05-05 Impact factor: 6.167
Authors: Hilary P Blumberg; Hoi-Chung Leung; Pawel Skudlarski; Cheryl M Lacadie; Carolyn A Fredericks; Brent C Harris; Dennis S Charney; John C Gore; John H Krystal; Bradley S Peterson Journal: Arch Gen Psychiatry Date: 2003-06
Authors: Chun S Zuo; Katherine A Davis; Madeline K Kuppe; M Kathryn Dahlgren; Staci Gruber; Garrett M Fitzmaurice; Scott E Lukas Journal: J Psychiatr Res Date: 2021-12-21 Impact factor: 4.791
Authors: Constance M Moore; Jean A Frazier; Carol A Glod; Janis L Breeze; Megan Dieterich; Chelsea T Finn; Blaise deB Frederick; Perry F Renshaw Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-04 Impact factor: 8.829
Authors: Henrique Soila Menossi; Anna E Goudriaan; Cintia de Azevedo-Marques Périco; Sérgio Nicastri; Arthur Guerra de Andrade; Gilberto D'Elia; Chiang-Shan R Li; João Mauricio Castaldelli-Maia Journal: CNS Drugs Date: 2013-11 Impact factor: 5.749
Authors: Aimie L Peek; Andrew M Leaver; Sheryl Foster; Georg Oeltzschner; Nicolaas A Puts; Graham Galloway; Michele Sterling; Karl Ng; Kathryn Refshauge; Maria-Eliza R Aguila; Trudy Rebbeck Journal: J Pain Date: 2021-06-25 Impact factor: 5.820